

Synthetic Skin-Permeable Proteins Enabling Needleless Immunization**

Yongzhuo Huang, Yoon Shin Park, Cheol Moon, Allan E. David, Hee Sun Chung, and Victor C. Yang*


Protein drugs, because of their large size and hydrophilic nature, are normally precluded from effective delivery such as cell entry or tissue diffusion. Among the transport barriers, the skin poses a formidable challenge to proteins because of the impermeable stratum corneum. The existing techniques for percutaneous protein delivery must rely on sophisticated delivery systems, such as the use of complicated nanocarriers or mechanical devices, to overcome the skin barrier for noninvasive delivery. A challenge in manufacturing such systems is the complicated processes and potential negative impact on protein drug stability. Moreover, the high manufacturing cost of these advanced systems often offsets their remarkable advantages.

To circumvent these problems that confront the current methods, we hypothesized the concept of “skin-permeable proteins”, which would possess skin-penetrating ability and thereby eliminate the need for a transport vehicle. However, naturally occurring proteins with skin-penetrating ability are rare. Herein, we present a novel strategy for chemically constructing artificial skin-permeable proteins, illustrated by the simple conjugation of a protein to a cell-penetrating peptide (CPP), which would display a penetration effect on the stratum corneum barrier and transport the attached proteins into the skin. Furthermore, the feasibility of application of the strategy in transcutaneous immunization (TI) is demonstrated.

CPPs are known for their versatility in carrying macro- or supramolecules through the cell membrane barriers that challenge the conventional drug-delivery approaches.^[1] The CPPs are capable of transporting their cargos, often linked by

a covalent bond, into almost all cell types.^[2] Among such CPPs, the low-molecular-weight protamine (LMWP) peptide (VSRRRRRRGGRRRR), developed in our laboratory by enzymatic digestion of protamine (an FDA-approved drug), offers distinct advantages. First, LMWP is as potent as the virus-derived TAT peptide, the most-studied CPP to date, in mediating cellular translocation of the attached cargos.^[3] Secondly, unlike other CPPs, the toxicity profile of LMWP has already been thoroughly established. LMWP was shown to be nonimmunogenic,^[4] and its use in dogs did not elicit acute toxic responses.^[5] Lastly, while other CPPs must be chemically synthesized, LMWP can be produced in mass quantities direct from native protamine with limited processing time and cost.^[6]

In this investigation, the artificial skin-permeable protein was synthesized by conjugating LMWP to ovalbumin (OVA), a representative antigenic protein, through a cleavable disulfide bond (Scheme 1). The LMWP–OVA conjugates were purified by heparin affinity chromatography, and the final product, generally possessing a 1:1 molar ratio of LMWP/OVA, was verified by MALDI-TOF mass spectrometry.



Scheme 1. Chemical conjugation of LMWP to OVA. SPDP = *N*-succinimidyl-3-(2-pyridyldithio)propionate.

As noted, skin keratinocytes are a physical barrier that provides the front line of defense against infection and also poses a challenge to protein delivery. On the other hand, keratinocytes execute a “part-time” antigen-presenting function by secreting immune mediators and transferring antigens to local antigen-presenting cells.^[7] LMWP was shown to

[*] Dr. Y. Huang, Dr. Y. S. Park, Dr. C. Moon, Dr. A. E. David, Dr. H. S. Chung, Prof. V. C. Yang
College of Pharmacy, University of Michigan
428 Church Street, Ann Arbor, MI 48109 (USA)
Fax: (+1) 734-763-9772
E-mail: vcyang@umich.edu
Homepage: http://pharmacy.umich.edu/pharmacy/victor_chi-min_yang

Prof. V. C. Yang
Tianjin Key Laboratory for Modern Drug Delivery and High Efficiency
Tianjin University, Tianjin 300072 (China)

[**] This study was supported by NIH R01 grant CA114612 and in part by the WCU Program funded by the MEST, South Korea (Grant No. R31-2008-000-10103-0). V.C.Y. is currently a Participating Faculty member at the Department of Molecular Medicine and Biopharmaceutical Sciences, Seoul National University, South Korea.

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/ange.200906153>.

exhibit an ability to translocate linked cargos of varying sizes into keratinocytes (Figure 1), thus demonstrating the potential for percutaneous protein delivery.




Figure 1. Uptake by human keratinocyte cells of a) rhodamine B, b) OVA, and c) bovine serum albumin (BSA) compared with those of d) LMWP–rhodamine B, e) LMWP–OVA, and f) LMWP–BSA conjugates. Protein cargos were labeled with fluorescein isothiocyanate.

The plausibility of percutaneous delivery *in vivo* was examined by topical application of LMWP-linked lysozyme, OVA, or bovine serum albumin (BSA), to represent a broad range of protein sizes. All the LMWP-linked proteins successfully penetrated the stratum corneum and accumulated primarily in the epidermis (Figure 2), whereas the control proteins without LMWP linkage remained on the surface of the skin.

The skin penetration mechanism of CPPs is still under debate. However, the interaction between CPP and the lipid bilayer is believed to play a major role in the cell penetration process.^[8] Skin permeability is governed by the physical state and structural organization of the extracellular lipids.^[9] Hence, the skin penetration function of LMWP could account for its interaction with the skin extracellular lipid matrices. Such interaction would lead to disruption of the ordered lipid orientation, thereby creating channels for transducing protein cargos through the stratum corneum.

As a typical example of protein percutaneous delivery, the immunological milieu of the skin is an ideal site for non-invasive vaccine delivery. The epidermis is rich in mature Langerhans cells (LCs), which represent a network of immune cells that underlie 25 % of the total surface area in human skin,^[10] and thus the epidermis is the target skin layer




Figure 2. *In vivo* transcutaneous delivery mediated by LMWP. a–c) Unmodified free lysozyme, OVA, and BSA, respectively; d–f) LMWP-linked lysozyme, OVA, and BSA, respectively. Arrows represent the direction of skin penetration.

for TI. TI can be achieved by topically applying antigens, which, with the aid of a transdermal delivery system, penetrate into the skin and subsequently elicit the desired immunity. The network of LCs acts as an immunological line of defense and initiates immune responses by conveying the captured antigens to other cells of the immune system, for example, lymphocytes, melanocytes, and Merkel cells.^[11] Therefore, the unique epidermal accumulation of the LMWP-linked proteins offers an ideal situation to alert such antigen-presenting cells.

The constructed skin-permeable antigen of LMWP–OVA was tested for the feasibility of TI on Balb/c mice. Humoral immunoglobulin G (IgG) is the primary protection induced by preventive vaccines to neutralize and eliminate pathogens. Figure 3a revealed that a significant elevation of anti-OVA IgG concentration in the blood was observed following topical application of LMWP–OVA with cholera toxin as adjuvant. The IgG levels in TI groups treated with a high (TI-H) and medium dose (TI-M) of antigen displayed no statistical differences ($p > 0.05$) from those in animals given OVA through the standard intramuscular (IM) immunization method (IM group). The control group, which received topical native OVA, exhibited markedly lower levels of IgG as a result of poor percutaneous absorption of unmodified OVA. These findings indicated that the epidermis-accumulated LMWP–OVA was captured by LCs, which subsequently migrated to lymphoid tissues and presented the antigens, effectively eliciting robust humoral immune responses. Furthermore, the disulfide linkage could be cleaved by the




Figure 3. In the TI study, mice were topically immunized with high (500 μ g; TI-H), medium (250 μ g; TI-M), and low doses (100 μ g; TI-L) of LMWP-OVA. a) High levels of anti-OVA IgG were observed in all TI groups, with no statistically significant difference between the TI-H ($^1p=0.529$) or TI-M ($^2p=0.150$) groups and the IM group. Importantly, significant elevation in b) sIgA concentrations ($^{1,2}p<0.01$) and c) IFN- γ levels ($^{1,2,3}p<0.01$) were achieved by TI with LMWP-OVA compared to that by IM injection of OVA ($n=10$).

elevated level of glutathione and reductase activity in the cytosol,^[12] which allowed release of OVA from LMWP and thus retention of a full intrinsic immunogenicity. As evidence, LMWP-OVA in the TI method triggered OVA-specific IgG responses comparable to the IM injection of OVA. Since the conjugation of LMWP to OVA might affect its intrinsic antigenic determinants, a cleavable linkage could ease such concerns.

TI shows advantages over conventional injection vaccination by offering the opportunity to elicit specific immune responses, such as targeted immunity to the female reproductive tract^[13] and a cytotoxic T lymphocyte (CTL) effect.^[14]

Secretory immunoglobulin A (sIgA) is the predominant humoral defense mechanism at the mucosal surface, and it therefore protects the host from initial infections. As shown in Figure 3b, the anti-OVA sIgA levels measured in vaginal secretions were significantly higher in the TI-H and TI-M groups than those in the IM group, thus confirming the promise of TI in achieving local protective immunity against female genital infection. Furthermore, interferon- γ (IFN- γ), the representative cytokine known to enhance the CD8⁺ CTL-mediated cytotoxicity against infected cells, was also present at a level significantly higher in the TI groups than in the IM group (Figure 3c). Notably, the local immune response in skin could also benefit from the production of high levels of IFN- γ , because of its effect on promoting CTL recognition of antigen molecules in keratinocytes^[15] and subsequently their expedited lysis.^[16]

In addition, a primer-boosters vaccination conducted by combining the IM injection of OVA with transcutaneous boosters of LMWP-OVA showed an immunity induction comparable to that of the multishot IM standard method (Supporting Information, Figure S1). The self-administrable boosters would eliminate follow-up visits to clinics for a multidose protocol. Hence, this immunization strategy could improve not only patient compliance but also vaccination coverage in underserved areas with limited medical settings.

In conclusion, this methodology for constructing artificial skin-permeable antigens may offer simple and needle-free vaccination modalities without the need for sophisticated drug carriers or expensive medical devices. Such a method could be beneficial especially to developing countries that struggle to fulfill effective vaccination coverage.

Received: November 2, 2009

Published online: March 15, 2010

Keywords: antigens · drug delivery · percutaneous absorption · protein modifications · vaccination

- [1] a) S. Keller, I. Sauer, H. Strauss, K. Gast, M. Dathe, M. Bienert, *Angew. Chem.* **2005**, *117*, 5386–5389; *Angew. Chem. Int. Ed.* **2005**, *44*, 5252–5255; b) Y. Lim, E. Lee, M. Lee, *Angew. Chem.* **2007**, *119*, 3545–3548; *Angew. Chem. Int. Ed.* **2007**, *46*, 3475–3478; c) Y. Lim, E. Lee, M. Lee, *Angew. Chem.* **2007**, *119*, 9169–9172; *Angew. Chem. Int. Ed.* **2007**, *46*, 9011–9014.
- [2] a) S. Fawell, J. Seery, Y. Daikh, C. Moore, L. Chen, B. Pepinsky, J. Barsoum, *Proc. Natl. Acad. Sci. USA* **1994**, *91*, 664–668; b) S. Lee, F. Liang, X. Guo, L. Xie, S. Cahill, M. Blumenstein, H. Yang, D. Lawrence, Z. Zhang, *Angew. Chem.* **2005**, *117*, 4314–4316; *Angew. Chem. Int. Ed.* **2005**, *44*, 4242–4244.
- [3] a) Y. Park, J. Liang, K. Ko, S. Kim, V. C. Yang, *J. Gene Med.* **2002**, *5*, 700–711; b) Y. Park, L. Chang, J. Liang, C. Moon, C. Chung, V. C. Yang, *FASEB J.* **2005**, *19*, 1555–1557.
- [4] B. Tsui, V. Singh, J. Liang, V. C. Yang, *Thromb. Res.* **2001**, *101*, 417–420.
- [5] L. Lee, L. Chang, S. Wroblewski, T. Wakefield, V. C. Yang, *AAPS J.* **2001**, *3*, 24–31.
- [6] L. Chang, H. Lee, Z. Yang, V. C. Yang, *AAPS J.* **2001**, *3*, 7–14.
- [7] G. Leggatt, L. Dunn, R. De Kluyver, T. Stewart, I. Frazer, *Immunol. Cell Biol.* **2002**, *80*, 415–424.
- [8] a) A. Mishra, V. Gordon, L. Yang, R. Coridan, G. Wong, *Angew. Chem.* **2008**, *120*, 3028–3031; *Angew. Chem. Int. Ed.* **2008**, *47*,

- 2986–2989; b) P. Joanne, C. Galanth, N. Goasdoué, P. Nicolas, S. Sagan, S. Lavielle, G. Chassaing, C. El Amri, I. Alves, *Biochim. Biophys. Acta Biomembr.* **2009**, *1788*, 1772–1781.
- [9] I. Plasencia, L. Norlen, L. Bagatolli, *Biophys. J.* **2007**, *93*, 3142–3155.
- [10] G. Glenn, D. Taylor, X. Li, S. Frankel, A. Montemarano, C. Alving, *Nat. Med.* **2000**, *6*, 1403–1406.
- [11] S. Babiuk, M. Baca-Estrada, L. Babiuk, C. Ewen, M. Foldvari, *J. Controlled Release* **2000**, *66*, 199–214.
- [12] G. Saito, J. Swanson, K. Lee, *Adv. Drug Delivery Rev.* **2003**, *55*, 199–215.
- [13] C. Gockel, S. Bao, K. Beagley, *Mol. Immunol.* **2000**, *37*, 537–544.
- [14] I. Belyakov, S. Hammond, J. Ahlers, G. Glenn, J. Berzofsky, *J. Clin. Invest.* **2004**, *113*, 998–1007.
- [15] D. Niederwieser, J. Aubock, J. Troppmair, M. Herold, G. Schuler, G. Boeck, J. Lotz, P. Fritsch, C. Huber, *J. Immunol.* **1988**, *140*, 2556–2564.
- [16] F. Symington, E. Santos, *J. Immunol.* **1991**, *146*, 2169–2175.
-